CJC-1295 DAC
CJC-1295 DAC is your body's "Smart Thermostat." Imagine your body usually adjusts its growth levels like a flickering light switch—on and off in short bursts...
Technical Overview
CJC-1295 DAC is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). By incorporating a Drug Affinity Complex (DAC), this peptide binds to circulating albumin, significantly extending its half-life and providing sustained stimulation of the pituitary gland.
⏱️ Pharmacokinetics
| Parameter | Value | Notes |
|---|---|---|
| Half-life | 6 - 8 Days | Exceptionally long due to albumin binding |
| Tmax | 24 - 48 Hours | Slow peak after subcutaneous injection |
| Biological Window | 7 - 10 Days | Sustained elevation of mean GH/IGF-1 levels |
Mechanism of Action
- GHRH Receptor Agonism: Binds to receptors on the pituitary to increase growth hormone production and release [PMID: 16352683].
- Drug Affinity Complex (DAC): Forms a covalent bond with serum albumin, shielding the peptide from enzymatic degradation and renal clearance for over a week.
- Sustained Baseline: Unlike natural GHRH, which creates a sharp "pulse," CJC-1295 DAC raises the overall baseline (trough) of growth hormone and IGF-1, creating a more continuous anabolic environment.
Layman's Explanation
CJC-1295 DAC is your body's "Smart Thermostat." Imagine your body usually adjusts its growth levels like a flickering light switch—on and off in short bursts. CJC-1295 DAC instead resets the entire "room temperature." It stays in your system for a whole week, giving your body a steady, constant nudge to produce more growth hormone. It’s the "long-haul" version of its cousins, designed for people who want steady results without daily injections.
️ Demographic Warnings & Precautions
️ Obesity & Metabolic State
"GH Bleed" Risk. Sustained elevation of growth hormone (the "GH bleed") can cause insulin resistance in obese individuals. Because it doesn't allow for a "rest period" between pulses, it may interfere with glucose clearance more than short-acting peptides. Monitor HbA1c closely.
Elderly (Advanced Age)
Maintenance of Vitality. While highly effective for restoring IGF-1 levels in the elderly, the sustained elevation may increase the risk of organomegaly (growth of internal organs) over long-term use. Cycling the peptide (e.g., 5 days on, 2 days off) is often recommended to maintain sensitivity [PMID: 41966639].
️ Heart & Cardiovascular Conditions
Cardiac Hypertrophy. Sustained elevation of IGF-1 can lead to growth of the heart muscle (Left Ventricular Hypertrophy). This is a significant risk for those with existing heart conditions. Patients with structural heart disease should avoid long-acting GH secretagogues [PMID: 38197510].
Upsides & Downsides
Upsides
- Infrequent Dosing: Only requires 1-2 injections per week.
- Potent IGF-1 Elevation: Can increase mean IGF-1 levels by 1.5x to 3x for up to 11 days.
- High Bioavailability: Nearly 100% of the dose binds to albumin and stays in the system.
Downsides
- Less Natural: Overrides the body's natural pulsatile rhythm of GH release.
- Insulin Resistance: Higher risk of affecting blood sugar compared to non-DAC versions.
- WADA Status: Banned for life in competitive sports.
Synergies
- Ipamorelin: Though CJC-1295 DAC provides a high baseline, adding Ipamorelin pulses provides a synergistic surge, mimicking both high baseline and sharp spikes of youth.
- BPC-157: Synergizes to repair tendons and ligaments; the GH provides the "fuel" while BPC-157 provides the "direction" of repair.
- Albumin-Rich Nutrition: Ensuring adequate protein intake is crucial as the peptide's delivery depends entirely on binding to serum albumin.
Key References
- [PMID: 16352683] - Prolonged Stimulation of Growth Hormone and IGF-I by CJC-1295 (2006).
- [PMID: 38197510] - Thomas A, et al. Chromatographic analysis of growth hormone-releasing hormones in doping control (2024).
- [PMID: 41490200] - Rahman OF, et al. Therapeutic Peptides in Orthopaedics: GHRH signaling (2026).
- [PMID: 41966639] - Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies (2026).